- Home
- XTLB vs FBRX Comparison
XTLB vs FBRX Comparison
Compare XTLB & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTLB
- FBRX
- Stock Information
- Founded
- XTLB 1993
- FBRX N/A
- Country
- XTLB Israel
- FBRX United States
- Employees
- XTLB N/A
- FBRX N/A
- Industry
- XTLB Biotechnology: Pharmaceutical Preparations
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- XTLB Health Care
- FBRX Health Care
- Exchange
- XTLB Nasdaq
- FBRX Nasdaq
- Market Cap
- XTLB 8.0M
- FBRX 8.3M
- IPO Year
- XTLB 2005
- FBRX N/A
- Fundamental
- Price
- XTLB $1.83
- FBRX $15.64
- Analyst Decision
- XTLB
- FBRX Strong Buy
- Analyst Count
- XTLB 0
- FBRX 3
- Target Price
- XTLB N/A
- FBRX $77.58
- AVG Volume (30 Days)
- XTLB 109.8K
- FBRX 1.5M
- Earning Date
- XTLB 11-26-2024
- FBRX 11-14-2024
- Dividend Yield
- XTLB N/A
- FBRX N/A
- EPS Growth
- XTLB N/A
- FBRX N/A
- EPS
- XTLB N/A
- FBRX N/A
- Revenue
- XTLB N/A
- FBRX N/A
- Revenue This Year
- XTLB N/A
- FBRX N/A
- Revenue Next Year
- XTLB N/A
- FBRX N/A
- P/E Ratio
- XTLB N/A
- FBRX N/A
- Revenue Growth
- XTLB N/A
- FBRX N/A
- 52 Week Low
- XTLB $0.76
- FBRX $4.11
- 52 Week High
- XTLB $4.99
- FBRX $21.25
- Technical
- Relative Strength Index (RSI)
- XTLB 46.62
- FBRX 92.83
- Support Level
- XTLB $1.70
- FBRX $5.55
- Resistance Level
- XTLB $1.85
- FBRX $18.81
- Average True Range (ATR)
- XTLB 0.13
- FBRX 1.51
- MACD
- XTLB 0.01
- FBRX 1.06
- Stochastic Oscillator
- XTLB 42.58
- FBRX 78.42
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).